Peer-reviewed veterinary case report
Blood test gene patterns predict long-term survival in dogs
By Rao, Kirthana et al.·Published in Scientific reports·2026·Department of Dermatology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Peripheral blood mononuclear cell gene expression signatures predict long-term survivorship in canine DLBCL.
- Species:
- dog
Plain-English summary
A group of dogs with diffuse large B cell lymphoma (DLBCL) received a combination treatment of a specific antibody and low-dose chemotherapy, followed by immune-modulating agents. Researchers monitored changes in certain immune-related genes in the dogs' blood to see if they could predict which dogs would relapse early or survive longer. They found that certain gene expressions were linked to shorter survival times, while others were associated with long-term survival. This information could help veterinarians identify dogs that may need more aggressive treatment sooner, improving their chances of a better outcome.
People also search for: dog lymphoma treatment · canine DLBCL survival rates · dog cancer gene testing
Abstract
Pet dogs spontaneously develop a form of diffuse large B cell lymphoma (DLBCL) that recapitulates many of the features of double hit (MYC/BCL2) human DLBCL. We recently completed a clinical trial in dogs with DLBCL using a combination of canine anti-CD20 antibody and low dose doxorubicin followed by one of three small molecule immune-modulating agents (KPT-9274, TAK-981 or RV1001). Clinical outcomes and tumor specific biomarkers of response from these dogs have been previously reported. In this study, we used the NanoString Canine IO panel to assess dynamic changes in gene counts from peripheral blood mononuclear cells (PBMCs) collected longitudinally from these from dogs over the course of their treatment to identify immune correlates associated with early relapse versus long-term survivorship. Increases in interferon-stimulated gene (ISG) signatures and immune skewing genes [CCR9, CD209 (DC-SIGN), CMKLR and DDX58 (RIG-I)] were associated with shorter (< 400 day) survival times and early relapse. In contrast, CD1E and CCL14 were elevated post-immunotherapy in long-term (> 400 day) survivors, suggesting that these may be associated with protective immune signatures. Examining genes that were expressed in short- versus long-term survivors early on in the treatment regimen identified TBHD, NPNT and ISG20 as elevated in dogs with shorter survival times at day 7. To facilitate point-of-care PBMC gene expression testing that could be used to distinguish those dogs likely to require more intensive treatment regimens in advance of relapse, we developed qPCR assays for TBHD, NPNT and ISG20. Together these data provide proof of principle that biomarker interrogation in PBMCs can help predict early relapse and poor responders to inform clinical management of DLBCL.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41844944/